Peregrine Ventures

Peregrine Ventures is Israel's first dedicated healthcare-focused venture capital fund, founded in 2001 in Or Yehuda by serial entrepreneur brothers Eyal Lifschitz (Co-Founder and General Managing Partner) and Boaz Lifschitz (Co-Founder and General Partner), who previously co-founded biomedical device companies Visioncare Ophthalmic Technologies and BioControl in the 1990s. The firm today manages approximately $600 million in assets across a multi-fund platform that pairs early-stage venture investing with Peregrine Growth, a $300 million late-stage life-sciences fund launched in November 2020, plus earlier funds including a $115 million med-tech vehicle. Partners Tamir Tal, Lior Shahory, David Eldar, and Shiran Tehila Mashiah complement the founding team. A distinctive feature of the platform is its embedded synergy with the Incentive Incubator, giving portfolio companies deep operating support from the pre-company stage through clinical and commercial scale-up. Peregrine leads rounds and has made approximately 172 investments into around 75 active and realized portfolio companies, with one unicorn, one IPO, and 16 acquisitions to date. Notable outcomes include Insightec, Quicklizard, and Eledon. Startup Nation Central named Peregrine Israel's most active healthtech investor for 2024, based on 15 strategic health-tech deals. The investment scope covers life sciences broadly: healthcare, digital health, medical devices, therapeutic devices, pharma, biotechnology, and medical software. Recent investments include Lutris Pharma ($30 million, January 2025) and Aluma Healthcare in September 2025. Peregrine's 25-year track record in Israeli healthcare and its deeply integrated incubator model create a continuum from scientific concept to clinical validation that few other investors can offer. By maintaining active involvement at every stage from incubation through growth equity, the firm builds durable portfolio relationships that extend well beyond a standard investment horizon.